The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets

References

• Egan B, Zierath J. Zierath Juleen R. Exercise Metabolism and the Molecular Regulation of Skeletal Muscle Adaptation. Cell Metab. 2013;17(2):162–184. doi:10.1016/j.cmet.2012.12.012
   PubMed Web of Science ®Google Scholar
• Metallo Christian M, Vander Heiden Matthew G. Understanding Metabolic Regulation and Its Influence on Cell Physiology. Molecular Cell. 2013;49(3):388–398. doi:10.1016/j.molcel.2013.01.018
   PubMed Web of Science ®Google Scholar
• Affourtit C. Mitochondrial involvement in skeletal muscle insulin resistance: a case of imbalanced bioenergetics. Biochimica et Biophysica Acta. 2016;1857(10):1678–1693.
   PubMed Web of Science ®Google Scholar
• Voet D, Voet J. Biochemistry. 4th ed. New York: Wiley & Sons; 2011.
   Google Scholar
• Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev. 2013;9(1):25–53. doi:10.2174/157339913804143225
   PubMedGoogle Scholar
• Hædersdal S, Lund A, Knop FK, Vilsbøll T. The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. Mayo Clin Proc. 2018;93(2):217–239. doi:10.1016/j.mayocp.2017.12.003
   PubMed Web of Science ®Google Scholar
• Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose Metabolism and Regulation: beyond Insulin and Glucagon. Diabetes Spectr. 2004;17(3):183–190. doi:10.2337/diaspect.17.3.183
   Google Scholar
• Dimitriadis G, Mitrou P, Lambadiari V, Maratou E, Raptis SA. Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract. 2011;93:S52–S59.
   PubMed Web of Science ®Google Scholar
• Röder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glucose homeostasis. Exp Mol Med. 2016;48(3):e219–e219.
   PubMed Web of Science ®Google Scholar
• Brereton MF, Vergari E, Zhang Q, Alpha- CA. Delta- and PP-cells: are They the Architectural Cornerstones of Islet Structure and Co-ordination?. J Histochem Cytochem. 2015;63(8):575–591. doi:10.1369/0022155415583535
   PubMed Web of Science ®Google Scholar
• De Graaf C, Donnelly D, Wootten D, et al. Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: a Long March to Therapeutic Successes. Pharmacol Rev. 2016;68(4):954–1013. doi:10.1124/pr.115.011395
   PubMed Web of Science ®Google Scholar
• Forbes JM, Cooper ME. Mechanisms of Diabetic Complications. Physiol Rev. 2013;93(1):137–188. doi:10.1152/physrev.00045.2011
   PubMed Web of Science ®Google Scholar
• Creutzfeldt W. The [pre-] history of the incretin concept. Regul Pept. 2005;128(2):87–91. doi:10.1016/j.regpep.2004.08.004
   PubMedGoogle Scholar
• Holst JJ. From the Incretin Concept and the Discovery of GLP-1 to Today’s Diabetes Therapy. Front Endocrinol. 2019;10:260.
   PubMed Web of Science ®Google Scholar
• Graaf C, Donnelly D, Wootten D, et al. Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: a Long March to Therapeutic Successes. Pharmacol Rev. 2016;68(4):954–1013.
   PubMed Web of Science ®Google Scholar
• Goldstein B, Wieland D. Type 2 Diabetes: Principles and Practice. Second Edition. ed. New York: Informa Healthcare; 2007.
   Google Scholar
• Salehi M, Aulinger B, D’Alessio D. Effect of Glycemia on Plasma Incretins and the Incretin Effect During Oral Glucose Tolerance Test. Diabetes. 2012;61(11):2728–2733. doi:10.2337/db11-1825
   PubMed Web of Science ®Google Scholar
• Reed J, Bain S, Kanamarlapudi V. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Diabetes Metab Syndr Obes. 2021;14:3567–3602. doi:10.2147/DMSO.S319895
   PubMed Web of Science ®Google Scholar
• Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–149. doi:10.1016/j.diabres.2013.11.002
   PubMed Web of Science ®Google Scholar
• Hinney A, Körner A, Fischer-Posovszky P. The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits. Nat Rev Endocrinol. 2022;18(10):623–637. doi:10.1038/s41574-022-00716-0
   PubMed Web of Science ®Google Scholar
• Doulla M, McIntyre AD, Hegele RA, Gallego PH. A novel MC4R mutation associated with childhood-onset obesity: a case report. Paediatrics Child Health. 2014;19(10):515–518. doi:10.1093/pch/19.10.515
   PubMed Web of Science ®Google Scholar
• Telci Caklili O, Cesur M, Mikhailidis DP, Rizzo M. Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: a Critical Overview. Int J Med. 2023;16:1767–1774. doi:10.2147/DMSO.S392684
   Google Scholar
• Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–223. doi:10.1038/s41573-021-00337-8
   PubMed Web of Science ®Google Scholar
• Gulinac M, Miteva DG, Peshevska-Sekulovska M, et al. Long-term effectiveness, outcomes and complications of bariatric surgery. World j Clin Cases. 2023;11(19):4504–4512. doi:10.12998/wjcc.v11.i19.4504
   PubMed Web of Science ®Google Scholar
• Ozougwu JC, Obimba KC, Belonwu CD, Unakalamba CB. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J Physiol Pathophysiol. 2013;4:46–57. doi:10.5897/JPAP2013.0001
   Google Scholar
• Thompson A, Kanamarlapudi V. Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling. Clin Exp Pharmacol. 2013;3.
   Google Scholar
• Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Chapter 1: epidemiology of Type 1 Diabetes. Endocrinol Metab Clinics North Am. 2010;39(3):481–497. doi:10.1016/j.ecl.2010.05.011
   PubMed Web of Science ®Google Scholar
• Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068–1083. doi:10.1016/S0140-6736(13)62154-6
   PubMed Web of Science ®Google Scholar
• Leahy JL. Pathogenesis of Type 2 Diabetes Mellitus. Archiv Med Res. 2005;36(3):197–209. doi:10.1016/j.arcmed.2005.01.003
   PubMed Web of Science ®Google Scholar
• Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus[mdash]present and future perspectives. Nat Rev Endocrinol. 2012;8(4):228–236. doi:10.1038/nrendo.2011.183
   Web of Science ®Google Scholar
• Raz I. Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes. Diabetes Care. 2013;36(Suppl 2):S139–S144. doi:10.2337/dcS13-2035
   PubMed Web of Science ®Google Scholar
• Reed J, Bain S, Kanamarlapudi V. Recent advances in understanding the role of glucagon-like peptide 1 [version 1; peer review: 2 approved]. F1000Research. 2020;9(239):1–14. doi:10.12688/f1000research.20602.1
   Google Scholar
• Moede T, Leibiger IB, Berggren P-O. Alpha cell regulation of beta cell function. Diabetologia. 2020;63(10):2064–2075. doi:10.1007/s00125-020-05196-3
   PubMed Web of Science ®Google Scholar
• Quesada I, Tudurí E, Ripoll C, Nadal Á. Physiology of the pancreatic α-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol. 2008;199(1):5–19. doi:10.1677/JOE-08-0290
   PubMed Web of Science ®Google Scholar
• Komatsu M, Takei M, Ishii H, Sato Y. Glucose-stimulated insulin secretion: a newer perspective. J Diabetes Invest. 2013;4(6):511–516. doi:10.1111/jdi.12094
   PubMed Web of Science ®Google Scholar
• Qaid MM, Abdelrahman MM. Role of insulin and other related hormones in energy metabolism—A review. Cogent Food Agric. 2016;2(1):1267691. doi:10.1080/23311932.2016.1267691
   Google Scholar
• Jain R, Lammert E. Cell–cell interactions in the endocrine pancreas. Diabetes Obesity Metab. 2009;11(s4):159–167. doi:10.1111/j.1463-1326.2009.01102.x
   PubMedGoogle Scholar
• Ionescu-Tirgoviste C, Gagniuc PA, Gubceac E, et al. A 3D map of the islet routes throughout the healthy human pancreas. Sci Rep. 2015;5(1):14634. doi:10.1038/srep14634
   PubMedGoogle Scholar
• Pugliese A. The Insulin Gene In Type 1 Diabetes. IUBMB Life. 2005;57(7):463–468. doi:10.1080/15216540500163301
   PubMed Web of Science ®Google Scholar
• Wilcox G. Insulin and Insulin Resistance. Clin Biochemist Rev. 2005;26(2):19–39.
   PubMedGoogle Scholar
• Affourtit C, Brand MD. On the role of uncoupling protein-2 in pancreatic beta cells. Biochimica et Biophysica Acta. 2008;1777(7–8):973–979. doi:10.1016/j.bbabio.2008.03.022
   PubMed Web of Science ®Google Scholar
• Affourtit C, Jastroch M, Brand MD. Uncoupling protein-2 attenuates glucose-stimulated insulin secretion in INS-1E insulinoma cells by lowering mitochondrial reactive oxygen species. Free Radic Biol Med. 2011;50(5):609–616. doi:10.1016/j.freeradbiomed.2010.12.020
   PubMed Web of Science ®Google Scholar
• Patzelt C, Labrecque AD, Duguid JR, et al. Detection and kinetic behavior of preproinsulin in pancreatic islets. Proc Natl Acad Sci USA. 1978;75(3):1260–1264. doi:10.1073/pnas.75.3.1260
   PubMed Web of Science ®Google Scholar
• Boland BB, Rhodes CJ, Grimsby JS. The dynamic plasticity of insulin production in β-cells. Mol Metabol. 2017;6(9):958–973. doi:10.1016/j.molmet.2017.04.010
   PubMed Web of Science ®Google Scholar
• Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: observations From the SAVOR-TIMI 53 Trial. Diabetes Care. 2015;38(4):696. doi:10.2337/dc14-1850
   PubMed Web of Science ®Google Scholar
• Rhodes CJ. Type 2 Diabetes-A Matter of ß-Cell Life and Death?. Science. 2005;307(5708):380. doi:10.1126/science.1104345
   PubMed Web of Science ®Google Scholar
• Matschinsky F, Liang Y, Kesavan P, et al. Glucokinase as pancreatic beta cell glucose sensor and diabetes gene. J Clin Investig. 1993;92(5):2092–2098. doi:10.1172/JCI116809
   PubMed Web of Science ®Google Scholar
• Affourtit C. Brand Martin D. Uncoupling protein-2 contributes significantly to high mitochondrial proton leak in INS-1E insulinoma cells and attenuates glucose-stimulated insulin secretion. Biochem. J. 2008;409(1):199–204. doi:10.1042/BJ20070954
   PubMedGoogle Scholar
• Rolfe DF, Brand MD. Contribution of mitochondrial proton leak to skeletal muscle respiration and to standard metabolic rate. Am J Physiol Cell Physiol. 1996;271(4):C1380–C1389. doi:10.1152/ajpcell.1996.271.4.C1380
   Web of Science ®Google Scholar
• Robson-Doucette CA, Sultan S, Allister EM, et al. β-Cell Uncoupling Protein 2 Regulates Reactive Oxygen Species Production, Which Influences Both Insulin and Glucagon Secretion. Diabetes. 2011;60(11):2710–2719. doi:10.2337/db11-0132
   PubMed Web of Science ®Google Scholar
• Ahmed Alfar E, Kirova D, Konantz J, Birke S, Mansfeld J, Ninov N. Distinct Levels of Reactive Oxygen Species Coordinate Metabolic Activity with Beta-cell Mass Plasticity. Sci Rep. 2017;7(1):3994. doi:10.1038/s41598-017-03873-9
   PubMedGoogle Scholar
• Lei XG, Vatamaniuk MZ. Two tales of antioxidant enzymes on β cells and diabetes. Antioxidants Redox Signaling. 2011;14(3):489–503. doi:10.1089/ars.2010.3416
   PubMed Web of Science ®Google Scholar
• Henquin J-C. The dual control of insulin secretion by glucose involves triggering and amplifying pathways in beta-cells. Diabetes Res Clin Pract. 2011;93:S27–S31.
   PubMed Web of Science ®Google Scholar
• Newsholme P, Krause M. Nutritional Regulation of Insulin Secretion: implications for Diabetes. Clin Biochem Rev. 2012;33(2):35–47.
   PubMedGoogle Scholar
• Wang Z, Thurmond DC. Mechanisms of biphasic insulin-granule exocytosis – roles of the cytoskeleton, small GTPases and SNARE proteins. J Cell Sci. 2009;122(7):893. doi:10.1242/jcs.034355
   PubMed Web of Science ®Google Scholar
• Rutter GA. Nutrient–secretion coupling in the pancreatic islet β-cell: recent advances. Mol Aspect Med. 2001;22(6):247–284. doi:10.1016/S0098-2997(01)00013-9
   PubMedGoogle Scholar
• Detimary P, Dejonghe S, Ling Z, Pipeleers D, Schuit F, Henquin JC. The changes in adenine nucleotides measured in glucose-stimulated rodent islets occur in beta cells but not in alpha cells and are also observed in human islets. J Biol Chem. 1998;273:1–4. doi:10.1074/jbc.273.51.33905
   PubMed Web of Science ®Google Scholar
• Ronner P, Naumann CM, Friel E. Effects of glucose and amino acids on free ADP in ßHC9 insulin-secreting cells. Diabetes. 2001;50:1–10. doi:10.2337/diabetes.50.2.291
   Google Scholar
• Zhang T, Li C. Mechanisms of amino acid-stimulated insulin secretion in congenital hyperinsulinism. Acta Biochim. Biophys. Sin. 2013;45(1):36–43. doi:10.1093/abbs/gms107
   Google Scholar
• Thorens B. Neural regulation of pancreatic islet cell mass and function. Diabetes Obesity Metab. 2014;16(S1):87–95. doi:10.1111/dom.12346
   PubMedGoogle Scholar
• Gromada J, Hughes TE. Ringing the dinner bell for insulin: muscarinic M3 receptor activity in the control of pancreatic β cell function. Cell Metab. 2006;3(6):390–392. doi:10.1016/j.cmet.2006.05.004
   PubMed Web of Science ®Google Scholar
• Lasschuijt MP, Mars M, de Graaf C, Smeets PAM. Endocrine Cephalic Phase Responses to Food Cues: a Systematic Review. Adv. Nutr. 2020;11(5):1364–1383. doi:10.1093/advances/nmaa059
   PubMed Web of Science ®Google Scholar
• Teff KL. How neural mediation of anticipatory and compensatory insulin release helps us tolerate food. Physiol Behav. 2011;103(1):44–50. doi:10.1016/j.physbeh.2011.01.012
   PubMed Web of Science ®Google Scholar
• Marliss EB, Vranic M. Intense Exercise Has Unique Effects on Both Insulin Release and Its Roles in Glucoregulation. Diabetes. 2002;51(suppl 1):S271–S283. doi:10.2337/diabetes.51.2007.S271
   PubMedGoogle Scholar
• Kong CC, Cheng JD, Wang W. Neurotransmitters regulate β cells insulin secretion: a neglected factor. World j Clin Cases. 2023;11(28):6670–6679. doi:10.12998/wjcc.v11.i28.6670
   PubMed Web of Science ®Google Scholar
• Leiss V, Flockerzie K, Novakovic A, et al. Insulin secretion stimulated by L-arginine and its metabolite L-ornithine depends on Gαi2. Am J Physio. 2014;307(9):E800–E812. doi:10.1152/ajpendo.00337.2014
   PubMedGoogle Scholar
• Yang J, Chi Y, Burkhardt BR, Guan Y, Wolf BA. Leucine metabolism in regulation of insulin secretion from pancreatic beta cells. Nutr Rev. 2010;68(5):270–279. doi:10.1111/j.1753-4887.2010.00282.x
   PubMed Web of Science ®Google Scholar
• Yanagisawa Y. How dietary amino acids and high protein diets influence insulin secretion. Physiological Reports. 2023;11(2):e15577. doi:10.14814/phy2.15577
   PubMed Web of Science ®Google Scholar
• Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011;124(21):2338–2349. doi:10.1161/CIRCULATIONAHA.111.041418
   PubMed Web of Science ®Google Scholar
• Henquin J-C. Paracrine and autocrine control of insulin secretion in human islets: evidence and pending questions. Am J Physiol Endocrinol Metab. 2020;320(1):E78–E86. doi:10.1152/ajpendo.00485.2020
   PubMed Web of Science ®Google Scholar
• Rhodes CJ, White MF, Leahy JL, Kahn SE. Direct Autocrine Action of Insulin on β-Cells: does It Make Physiological Sense?. Diabetes. 2013;62(7):2157–2163. doi:10.2337/db13-0246
   PubMed Web of Science ®Google Scholar
• Wicksteed B, Alarcon C, Briaud I, Lingohr MK, Rhodes CJ. Glucose-induced Translational Control of Proinsulin Biosynthesis Is Proportional to Preproinsulin mRNA Levels in Islet β-Cells but Not Regulated via a Positive Feedback of Secreted Insulin. J Biol Chem. 2003;278(43):42080–42090. doi:10.1074/jbc.M303509200
   PubMed Web of Science ®Google Scholar
• Hunter SJ, Garvey WT. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system 1. Am j Med. 1998;105(4):331–345. doi:10.1016/S0002-9343(98)00300-3
   PubMed Web of Science ®Google Scholar
• Huang S, Czech MP. The GLUT4 Glucose Transporter. Cell Metab. 2007;5(4):237–252. doi:10.1016/j.cmet.2007.03.006
   PubMed Web of Science ®Google Scholar
• Mandarino LJ, Printz RL, Cusi KA, et al. Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle. Am J Physio. 1995;269(4):E701–E708. doi:10.1152/ajpendo.1995.269.4.E701
   PubMedGoogle Scholar
• Rossetti L, Hu M. Skeletal muscle glycogenolysis is more sensitive to insulin than is glucose transport/phosphorylation. Relation to the insulin-mediated inhibition of hepatic glucose production. J Clin Investig. 1993;92(6):2963–2974. doi:10.1172/JCI116919
   PubMed Web of Science ®Google Scholar
• Kawamori D, Kurpad AJ, Hu J, et al. Insulin Signaling in α-cells Modulates Glucagon Secretion in vivo. Cell Metab. 2009;9(4):350–361. doi:10.1016/j.cmet.2009.02.007
   PubMed Web of Science ®Google Scholar
• Xu GG, Rothenberg PL. Insulin Receptor Signaling in the β-Cell Influences Insulin Gene Expression and Insulin Content: evidence for Autocrine β-Cell Regulation. Diabetes. 1998;47(8):1243–1252. doi:10.2337/diab.47.8.1243
   PubMed Web of Science ®Google Scholar
• Skovsø S, Panzhinskiy E, Kolic J, et al. Beta-cell specific Insr deletion promotes insulin hypersecretion and improves glucose tolerance prior to global insulin resistance. Nat Commun. 2022;13(1):735. doi:10.1038/s41467-022-28039-8
   PubMed Web of Science ®Google Scholar
• Thomas DM, Udagawa N, Hards DK, et al. Insulin receptor expression in primary and cultured osteoclast-like cells. Bone. 1998;23(3):181–186. doi:10.1016/S8756-3282(98)00095-7
   PubMed Web of Science ®Google Scholar
• Stockhorst U, de Fries D, Steingrueber H-J, Scherbaum WA. Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol Behav. 2004;83(1):47–54. doi:10.1016/S0031-9384(04)00348-8
   PubMed Web of Science ®Google Scholar
• Agrawal R, Reno CM, Sharma S, Christensen C, Huang Y, Fisher SJ. Insulin action in the brain regulates both central and peripheral functions. Am J Physiol Endocrinol Metab. 2021;321(1):E156–E163. doi:10.1152/ajpendo.00642.2020
   PubMed Web of Science ®Google Scholar
• Gerozissis K. Brain insulin and feeding: a bi-directional communication. Eur. J. Pharmacol. 2004;490(1–3):59–70. doi:10.1016/j.ejphar.2004.02.044
   PubMed Web of Science ®Google Scholar
• Csajbók ÉA, Tamás G. Cerebral cortex: a target and source of insulin?. Diabetologia. 2016;59(8):1609–1615. doi:10.1007/s00125-016-3996-2
   PubMed Web of Science ®Google Scholar
• Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obesity Rev. 2007;8(1):21–34. doi:10.1111/j.1467-789X.2006.00270.x
   PubMed Web of Science ®Google Scholar
• Paz-Filho G, Mastronardi C, Delibasi T, Wong M-L, Licinio J. Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy. Arquivos brasileiros de endocrinologia e metabologia. 2010;54(8):690–697. doi:10.1590/S0004-27302010000800005
   PubMedGoogle Scholar
• Lee B, Shao J. Adiponectin and Energy Homeostasis. Rev Endocr Metab Disord. 2014;15(2):149–156. doi:10.1007/s11154-013-9283-3
   PubMed Web of Science ®Google Scholar
• Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obesity Rev. 2005;6(1):13–21. doi:10.1111/j.1467-789X.2005.00159.x
   PubMed Web of Science ®Google Scholar
• Qiao L, Kinney B, Schaack J, Shao J. Adiponectin Inhibits Lipolysis in Mouse Adipocytes. Diabetes. 2011;60(5):1519–1527. doi:10.2337/db10-1017
   PubMed Web of Science ®Google Scholar
• Kim J-Y, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007;117(9):2621–2637. doi:10.1172/JCI31021
   PubMed Web of Science ®Google Scholar
• Haugen F, Jørgensen A, Drevon CA, Trayhurn P. Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes. FEBS Lett. 2001;507(1):105–108. doi:10.1016/S0014-5793(01)02968-4
   PubMed Web of Science ®Google Scholar
• Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br. J. Pharmacol. 2012;165(3):622–632. doi:10.1111/j.1476-5381.2011.01369.x
   PubMed Web of Science ®Google Scholar
• Hasegawa G, Ohta M, Ichida Y, et al. Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity. Acta Diabetologica. 2005;42(2):104–109. doi:10.1007/s00592-005-0187-x
   PubMed Web of Science ®Google Scholar
• Iqbal N, Seshadri P, Stern L, et al. Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol Sci. 2005;9:161–165.
   PubMedGoogle Scholar
• Laudes M, Oberhauser F, Schulte DM, et al. Visfatin/PBEF/Nampt and Resistin Expressions in Circulating Blood Monocytes are Differentially Related to Obesity and Type 2 Diabetes in Humans. Horm Metab Res. 2010;42(04):268–273. doi:10.1055/s-0029-1243638
   PubMedGoogle Scholar
• Siddiqui K, Scaria Joy S, George TP. Circulating resistin levels in relation with insulin resistance, inflammatory and endothelial dysfunction markers in patients with type 2 diabetes and impaired fasting glucose. EndocrineMetab Sci. 2020;1(3):100059. doi:10.1016/j.endmts.2020.100059
   Google Scholar
• Milan G, Granzotto M, Scarda A, et al. Resistin and Adiponectin Expression in Visceral Fat of Obese Rats: effect of Weight Loss. Obesity Res. 2002;10(11):1095–1103.
   PubMedGoogle Scholar
• Wu G, Meininger CJ. Nitric oxide and vascular insulin resistance. BioFactors. 2009;35(1):21–27. doi:10.1002/biof.3
   PubMed Web of Science ®Google Scholar
• Sechi L, Bartoli E. Molecular mechanisms of insulin resistance in arterial hypertension. Blood Press Suppl. 1996;1:47–54.
   PubMedGoogle Scholar
• Pradhan G, Samson SL, Sun Y. Ghrelin: much more than a hunger hormone. Curr Opin Clin Nutr Metab Care. 2013;16(6):619–624. doi:10.1097/MCO.0b013e328365b9be
   PubMed Web of Science ®Google Scholar
• Yin X, Yin L, Geyang X, Wenjiao A, Zhang W. Ghrelin fluctuation, what determines its production?. Acta Biochim Biophys Sin. 2009;41(3):188–197. doi:10.1093/abbs/gmp001
   Google Scholar
• Gagnon J, Anini Y. Insulin and Norepinephrine Regulate Ghrelin Secretion from a Rat Primary Stomach Cell Culture. Endocrinology. 2012;153(8):3646–3656. doi:10.1210/en.2012-1040
   PubMed Web of Science ®Google Scholar
• Tadahiro Kitamura CRK, Accili D. Insulin Receptor Knockout Mice. Annual Review of Physiol. 2003;65(1):313–332. doi:10.1146/annurev.physiol.65.092101.142540
   PubMedGoogle Scholar
• Bunner AE, Chandrasekera PC, Barnard ND. Knockout mouse models of insulin signaling: relevance past and future. World J Diabetes. 2014;5(2):146–159. doi:10.4239/wjd.v5.i2.146
   PubMedGoogle Scholar
• Zahradka P, Werner J, Yau L. Expression and regulation of the insulin-like growth factor-1 receptor by growing and quiescent H4IIE hepatoma. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1998;1375(1–2):131–139. doi:10.1016/S0005-2736(98)00144-8
   PubMed Web of Science ®Google Scholar
• Kim W, Egan JM. The Role of Incretins in Glucose Homeostasis and Diabetes Treatment. Pharmacol Rev. 2008;60(4):470–512. doi:10.1124/pr.108.000604
   PubMed Web of Science ®Google Scholar
• Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiol Rev. 2007;87(4):1409–1439. doi:10.1152/physrev.00034.2006
   PubMed Web of Science ®Google Scholar
• Donath MY, Burcelin R. GLP-1 Effects on Islets: hormonal, Neuronal, or Paracrine?. Diabetes Care. 2013;36(Suppl 2):S145–S148. doi:10.2337/dcS13-2015
   PubMedGoogle Scholar
• Hinnen D. Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. Diabetes Spectr. 2017;30(3):202. doi:10.2337/ds16-0026
   PubMedGoogle Scholar
• Jacobson DA, Wicksteed BL, Philipson LH. The α-Cell Conundrum: ATP-Sensitive K+Channels and Glucose Sensing. Diabetes. 2009;58(2):304–306. doi:10.2337/db08-1618
   PubMed Web of Science ®Google Scholar
• Gylfe E. Glucose Control of Glucagon Secretion: there Is More to It Than KATP Channels. Diabetes. 2013;62(5):1391–1393. doi:10.2337/db13-0193
   PubMed Web of Science ®Google Scholar
• Reed J, Kanamarlapudi V. GLP-1. In: Choi S, editor. Encyclopedia of Signaling Molecules. Cham: Springer International Publishing; 2018:2098–2106.
   Google Scholar
• Taborsky GJ. The Physiology of Glucagon. J Diabetes Sci Technol. 2010;4(6):1338–1344. doi:10.1177/193229681000400607
   PubMedGoogle Scholar
• Christensen M, Bagger JI, Vilsboll T, Knop FK. The Alpha-Cell as Target for Type 2 Diabetes Therapy. Rev Diabetic Stud. 2011;8(3):369–381. doi:10.1900/RDS.2011.8.369
   PubMedGoogle Scholar
• Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physio. 2003;284(4):E671–E678. doi:10.1152/ajpendo.00492.2002
   PubMed Web of Science ®Google Scholar
• Leibiger B, Moede T, Muhandiramlage TP, et al. Glucagon regulates its own synthesis by autocrine signaling. Proc Natl Acad Sci USA. 2012;109(51):20925–20930. doi:10.1073/pnas.1212870110
   PubMed Web of Science ®Google Scholar
• Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschöp MH. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010;6(12):689–697. doi:10.1038/nrendo.2010.187
   PubMed Web of Science ®Google Scholar
• Huypens P, Ling Z, Pipeleers D, Schuit F. Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia. 2000;43(8):1012–1019. doi:10.1007/s001250051484
   PubMed Web of Science ®Google Scholar
• Doyle ME, Egan JM. Mechanisms of Action of GLP-1 in the Pancreas. Pharmacol Ther. 2007;113(3):546–593.
   PubMed Web of Science ®Google Scholar
• Seino Y, Fukushima M, Yabe D. GIP and GLP‐1, the two incretin hormones: similarities and differences. J Diabetes Invest. 2010;1(1–2):8–23. doi:10.1111/j.2040-1124.2010.00022.x
   PubMed Web of Science ®Google Scholar
• Ahrén B, Yamada Y, Seino Y. The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice. Peptides. 2021;135:170434. doi:10.1016/j.peptides.2020.170434
   PubMed Web of Science ®Google Scholar
• Condon JR. Glucagon in the Treatment of Paget’s Disease of Bone. Br Med J. 1971;4(5789):5789):719–721. doi:10.1136/bmj.4.5789.719
   Google Scholar
• Guo H, Sui C, Ge S, et al. Positive association of glucagon with bone turnover markers in type 2 diabetes: a cross-sectional study. Diabetes/Metab Res Rev. 2022;38(6):e3550. doi:10.1002/dmrr.3550
   PubMed Web of Science ®Google Scholar
• Al-Massadi O, Fernø J, Diéguez C, Nogueiras R, Quiñones M. Glucagon Control on Food Intake and Energy Balance. Int J Mol Sci. 2019;20(16):3905. doi:10.3390/ijms20163905
   PubMed Web of Science ®Google Scholar
• Sipos B, Sperveslage J, Anlauf M, et al. Glucagon Cell Hyperplasia and Neoplasia With and Without Glucagon Receptor Mutations. J Clin Endocrinol Metab. 2015;100(5):E783–E788. doi:10.1210/jc.2014-4405
   PubMed Web of Science ®Google Scholar
• Yu R. Pancreatic α-Cell Hyperplasia: facts and Myths. J Clin Endocrinol Metab. 2014;99(3):748–756. doi:10.1210/jc.2013-2952
   PubMed Web of Science ®Google Scholar
• Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA. 2003;100(3):1438–1443. doi:10.1073/pnas.0237106100
   PubMed Web of Science ®Google Scholar
• Hauge-Evans A, Bowe K, Franklin Z, Hassan Z, Jones P. Inhibitory effect of somatostatin on insulin secretion is not mediated via the CNS. J Endocrinol. 2015;225(1):19–26. doi:10.1530/JOE-14-0709
   PubMed Web of Science ®Google Scholar
• Grigoryan M, Kedees MH, Charron MJ, Guz Y, Teitelman G. Regulation of Mouse Intestinal L Cell Progenitors Proliferation by the Glucagon Family of Peptides. Endocrinology. 2012;153(7):3076–3088. doi:10.1210/en.2012-1120
   PubMed Web of Science ®Google Scholar
• Sinclair EM, Yusta B, Streutker C, et al. Glucagon Receptor Signaling Is Essential for Control of Murine Hepatocyte Survival. Gastroenterology. 2015;135(6):2096–2106. doi:10.1053/j.gastro.2008.07.075
   Google Scholar
• Krejs G. Physiological role of somatostatin in the digestive tract: gastric acid secretion, intestinal absorption, and motility. Scand J Gastroenterol Suppl. 1986;119(sup119):47–53. doi:10.3109/00365528609087431
   PubMedGoogle Scholar
• Lengyel A-MJ. Novel mechanisms of growth hormone regulation: growth hormone-releasing peptides and ghrelin. Braz J Med Biol Res. 2006;39(8):1003–1011. doi:10.1590/S0100-879X2006000800002
   PubMed Web of Science ®Google Scholar
• Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine. 2003;20(3):255–264. doi:10.1385/ENDO:20:3:255
   PubMed Web of Science ®Google Scholar
• Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biology Med. 1997;70(5–6):471–479.
   PubMed Web of Science ®Google Scholar
• Rutter GA. Regulating Glucagon Secretion: somatostatin in the Spotlight. Diabetes. 2009;58(2):299–301. doi:10.2337/db08-1534
   PubMed Web of Science ®Google Scholar
• Barden N, Lavoie M, Dupont A, Cote J, Cote J. Stimulation of glucagon release by addition of anti-somatostatin serum to islet of Langerhans in vitro. Endocrinology. 1977;101:635–638. doi:10.1210/endo-101-2-635
   PubMed Web of Science ®Google Scholar
• Gerich J, Lorenzi M, Schneider V, et al. Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and in insulin-dependent diabetics. Diabetes. 1974;23(11):876–880. doi:10.2337/diab.23.11.876
   PubMed Web of Science ®Google Scholar
• Kr BFC, Moldovan S, Nguyen TH, Watt PC, Walsh J, Gingerich R. Immunoneutralization of somatostatin, insulin, and glucagon causes alterations in islet cell secretion in the isolated perfused human pancreas. Pancreas. 2001;23(3):302–308. doi:10.1097/00006676-200110000-00012
   PubMed Web of Science ®Google Scholar
• Kawai K, Ol IE, Perrelet A, U RH. Circulating somatostatin acts on the islets of Langerhans by way of a somatostatin-poor compartment. Science. 1982;218(4571):477–478. doi:10.1126/science.6126931
   PubMed Web of Science ®Google Scholar
• Cejvan K, Coy DH, Efendic S. Intra-Islet Somatostatin Regulates Glucagon Release via Type 2 Somatostatin Receptors in Rats. Diabetes. 2003;52(5):1176–1181. doi:10.2337/diabetes.52.5.1176
   PubMed Web of Science ®Google Scholar
• Luque R, Kineman R. Gender-Dependent Role of Endogenous Somatostatin in Regulating Growth Hormone-Axis Function in Mice. Endocrinology. 2007;148(12):5998–6006. doi:10.1210/en.2007-0946
   PubMed Web of Science ®Google Scholar
• Hauge-Evans AC, King AJ, Carmignac D, et al. Somatostatin Secreted by Islet δ-Cells Fulfills Multiple Roles as a Paracrine Regulator of Islet Function. Diabetes. 2009;58(2):403–411. doi:10.2337/db08-0792
   PubMed Web of Science ®Google Scholar
• Hauge-Evans A, Bowe J, Franklin Z, Hassan Z, Jones P. Inhibitory effect of somatostatin on insulin secretion is not mediated via the CNS. J Endocrinol. 2015;225(1):19–26.
   PubMed Web of Science ®Google Scholar
• Pais R, Gribble FM, Reimann F. Stimulation of incretin secreting cells. Ther Adv Endocrinol Metab. 2016;7(1):24–42. doi:10.1177/2042018815618177
   PubMed Web of Science ®Google Scholar
• Svendsen B, Holst JJ. Paracrine regulation of somatostatin secretion by insulin and glucagon in mouse pancreatic islets. Jan. 2021;64(1):142–151.
   Google Scholar
• Lieverse R, Jansen J, Masclee A, Lamers C. Effects of somatostatin on human satiety. Neuroendocrinology. 1995;61(2):112–116. doi:10.1159/000126831
   PubMed Web of Science ®Google Scholar
• Nishi S, Seino Y, Ishida H, et al. Vagal regulation of insulin, glucagon, and somatostatin secretion in vitro in the rat. J Clin Investig. 1987;79(4):1191–1196. doi:10.1172/JCI112936
   PubMed Web of Science ®Google Scholar
• Floyd JJ, Fajans S, Pek S, Chance R. A newly recognized pancreatic polypeptide; plasma levels in health and disease. Recent Prog Horm Res. 1976;33:519–570. doi:10.1016/b978-0-12-571133-3.50019-2
   PubMedGoogle Scholar
• Aragón F, Karaca M, Novials A, Maldonado R, Maechler P, Rubí B. Pancreatic polypeptide regulates glucagon release through PPYR1 receptors expressed in mouse and human alpha-cells. Biochimica et Biophysica Acta. 2015;1850(2):343–351. doi:10.1016/j.bbagen.2014.11.005
   PubMed Web of Science ®Google Scholar
• Fetissov SO, Kopp J, Hökfelt T. Distribution of NPY receptors in the hypothalamus. Neuropeptides. 2004;38(4):175–188. doi:10.1016/j.npep.2004.05.009
   PubMed Web of Science ®Google Scholar
• Dembiński A, Warzecha Z, Ceranowicz P, et al. Influence of central and peripheral administration of pancreatic polypeptide on gastric mucosa growth. J Physiol Pharmacol. 2004;55(1 Pt 2):223–237.
   PubMed Web of Science ®Google Scholar
• Adrian TE, Greenberg GR, Barnes AJ, Christofides ND, Alberti KG, B SR. Effects of pancreatic polypeptide on motilin and circulation metabolites in man. Eur J Clin Invest. 1980;10:235–240. doi:10.1111/j.1365-2362.1980.tb00026.x
   PubMed Web of Science ®Google Scholar
• Khan D, Vasu S, Moffett RC, Irwin N, Flatt PR. Influence of neuropeptide Y and pancreatic polypeptide on islet function and beta-cell survival. Biochimica et Biophysica Acta. 2017;1861(4):749–758. doi:10.1016/j.bbagen.2017.01.005
   Web of Science ®Google Scholar
• Kim W, Fiori JL, Shin Y-K, et al. Pancreatic polypeptide inhibits somatostatin secretion. FEBS Lett. 2014;588(17):3233–3239. doi:10.1016/j.febslet.2014.07.005
   PubMed Web of Science ®Google Scholar
• Brunicardi FC, Chaiken RL, Ryan AS, et al. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab. 1996;81(10):3566–3572.
   PubMed Web of Science ®Google Scholar
• Seymour N, Brunicardi F, Chaiken R, et al. Reversal of abnormal glucose production after pancreatic resection by pancreatic polypeptide administration in man. Surgery. 1988;104(2):119–129.
   PubMed Web of Science ®Google Scholar
• Goldstein J, Kirwin J, Seymour N, Trachtenberg J, Rademaker E, Andersen D. Reversal of in vitro hepatic insulin resistance in chronic pancreatitis by pancreatic polypeptide in the rat. Surgery. 1989;106:1132–1133.
   Web of Science ®Google Scholar
• Jesudason DR, Monteiro MP, McGowan BMC, et al. Low-dose pancreatic polypeptide inhibits food intake in man. Br. J. Nutr. 2007;97(3):426–429. doi:10.1017/S0007114507336799
   PubMed Web of Science ®Google Scholar
• Batterham RL, Le Roux CW, Cohen MA, et al. Pancreatic Polypeptide Reduces Appetite and Food Intake in Humans. J Clin Endocrinol Metab. 2003;88(8):3989–3992. doi:10.1210/jc.2003-030630
   PubMed Web of Science ®Google Scholar
• Berntson GG, Zipf WB, Tm O, Hoffman JA, Chance RE. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides. 1993;14(3):497–503. doi:10.1016/0196-9781(93)90138-7
   PubMed Web of Science ®Google Scholar
• Asakawa A, Inui A, Yuzuriha H, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology. 2003;124(5):1325–1336. doi:10.1016/S0016-5085(03)00216-6
   PubMed Web of Science ®Google Scholar
• Adamska E, Ostrowska L, Górska M, Krętowski A. The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes. Prz Gastroenterol. 2014;9(2):69–76. doi:10.5114/pg.2014.42498
   PubMedGoogle Scholar
• Adrian TE, Besterman HS, Mallinson CN, Greenberg GR, Bloom SR. Inhibition of secretin stimulated pancreatic secretion by pancreatic polypeptide. Gut. 1979;20(1):37–40. doi:10.1136/gut.20.1.37
   PubMed Web of Science ®Google Scholar
• Akamizu T, Takaya K, Irako T, et al. Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocrinol. 2004;150(4):447–455. doi:10.1530/eje.0.1500447
   PubMed Web of Science ®Google Scholar
• Yin X, Li Y, Xu G, An W, Zhang W. Ghrelin fluctuation, what determines its production?. Acta Biochim. Biophys. Sin. 2009;41(3):188–197.
   Google Scholar
• Müller TD, Nogueiras R, Andermann ML, et al. Ghrelin. Mol Metabol. 2015;4(6):437–460. doi:10.1016/j.molmet.2015.03.005
   PubMed Web of Science ®Google Scholar
• Sato T, Nakamura Y, Shiimura Y, Ohgusu H, Kangawa K, Kojima M. Structure, regulation and function of ghrelin. J Biochem. 2012;151(2):119–128. doi:10.1093/jb/mvr134
   PubMed Web of Science ®Google Scholar
• Date Y, Nakazato M, Murakami N, Kojima M, Kangawa K, Matsukura S. Ghrelin Acts in the Central Nervous System to Stimulate Gastric Acid Secretion. Biochem. Biophys. Res. Commun. 2001;280(3):904–907. doi:10.1006/bbrc.2000.4212
   PubMed Web of Science ®Google Scholar
• DiGruccio MR, Mawla AM, Donaldson CJ, et al. Comprehensive alpha, beta and delta cell transcriptomes reveal that ghrelin selectively activates delta cells and promotes somatostatin release from pancreatic islets. Mol Metabol. 2016;5(7):449–458. doi:10.1016/j.molmet.2016.04.007
   PubMed Web of Science ®Google Scholar
• Churm R, Davies J, Stephens J, Prior S. Ghrelin function in human obesity and type 2 diabetes: a concise review: ghrelin in human obesity and diabetes. Obesity Reviews : an Official Journal of the International Association for the Study of Obesity. 2016;18(2):140–148. doi:10.1111/obr.12474
   PubMed Web of Science ®Google Scholar
• Ahima RS. Ghrelin—a new player in glucose homeostasis?. Cell Metab. 2006;3(5):301–302. doi:10.1016/j.cmet.2006.04.006
   PubMed Web of Science ®Google Scholar
• Lindqvist A, Shcherbina L, Prasad RB, et al. Ghrelin suppresses insulin secretion in human islets and type 2 diabetes patients have diminished islet ghrelin cell number and lower plasma ghrelin levels. Mol Cell Endocrinol. 2020;511:110835. doi:10.1016/j.mce.2020.110835
   PubMed Web of Science ®Google Scholar
• Lv Y, Liang T, Wang G, Li Z. Ghrelin, a gastrointestinal hormone, regulates energy balance and lipid metabolism. Biosci Rep. 2018;38(5):BSR20181061. doi:10.1042/BSR20181061
   PubMedGoogle Scholar
• Wells T. Ghrelin – defender of fat. Prog Lipid Res. 2009;48(5):257–274. doi:10.1016/j.plipres.2009.04.002
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. The Origin and Understanding of the Incretin Concept. Front Endocrinol. 2018;9:387. doi:10.3389/fendo.2018.00387
   PubMed Web of Science ®Google Scholar
• Moore B. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J. 1906;1:28–38. doi:10.1042/bj0010028
   PubMedGoogle Scholar
• Zunz E, LaBarre J. Hyperinsulinémie consécutive a l’injection de solution de secrétine non hypotensive. C R Soc Biol. 1928;98:1435–1438.
   Google Scholar
• La Barre J. Sur les possibilite’sd’un traitement du diabète par l’incrétine. Bull Acad R Med Belg. 1932;12:14.
   Google Scholar
• Elrick H, Stimmler L, Hlad CJ, Arai Y. PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION. J Clin Endocrinol Metab. 1964;24(10):1076–1082. doi:10.1210/jcem-24-10-1076
   PubMed Web of Science ®Google Scholar
• McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet. 1964;2(7349):20–21. doi:10.1016/S0140-6736(64)90011-X
   PubMedGoogle Scholar
• Perley M, Kipnis D. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest. 1967;46(1954–1962):1954–1962. doi:10.1172/JCI105685
   PubMedGoogle Scholar
• Brown JCDJ, Ross SA, Dupré J. Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res. 1975;31:487–532. doi:10.1016/b978-0-12-571131-9.50017-7
   PubMedGoogle Scholar
• Elahi D, Andersen D, Brown J, et al. Pancreatic alpha- and beta-cell responses to GIP infusion in normal man. Am J Physiol. 1979;237:185–191.
   PubMed Web of Science ®Google Scholar
• Ebert R, Creutzfeldt W. Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats. Endocrinology. 1982;111(5):1601–1606. doi:10.1210/endo-111-5-1601
   PubMed Web of Science ®Google Scholar
• Wt SD, Roth SE, Brenner MJ. Cell-free synthesis and processing of multiple precursors to glucagon. Nature. 1981;289:511–514. doi:10.1038/289511a0
   PubMed Web of Science ®Google Scholar
• Wg MS, Habener JF. Insulinotropin: glucagon-like peptide 1 (737) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987;79:616–619. doi:10.1172/JCI112855
   PubMed Web of Science ®Google Scholar
• Yamada Y, Tsukiyama K, Sato T, Shimizu T, Fujita H, Narita T. Novel extrapancreatic effects of incretin. J Diabetes Invest. 2016;7(S1):76–79. doi:10.1111/jdi.12495
   PubMedGoogle Scholar
• Dd BPL. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Recept Channels. 2002;8:179–188. doi:10.1080/10606820213687
   PubMedGoogle Scholar
• Wang X, Liu H, Chen J, Li Y, Qu S. Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1. Int J Endocrinol. 2015;2015:11. doi:10.1155/2015/651757
   Web of Science ®Google Scholar
• Ahlkvist L, Vikman J, Pacini G, Ahrén B. Synergism by individual macronutrients explains the marked early GLP-1 and islet hormone responses to mixed meal challenge in mice. Regul Pept. 2012;178(1):29–35. doi:10.1016/j.regpep.2012.06.004
   PubMedGoogle Scholar
• Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obesity Metab. 2013;15(1):15–27. doi:10.1111/j.1463-1326.2012.01663.x
   PubMed Web of Science ®Google Scholar
• Padidela R, Patterson M, Sharief N, Ghatei M, Hussain K. Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period. Eur J Endocrinol. 2009;160(1):53–58. doi:10.1530/EJE-08-0807
   PubMed Web of Science ®Google Scholar
• Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab. 2013;24(2):85–91. doi:10.1016/j.tem.2012.11.008
   PubMed Web of Science ®Google Scholar
• Anini Y, Hansotia T, Brubaker PL. Muscarinic Receptors Control Postprandial Release of Glucagon-Like Peptide-1: in Vivo and in Vitro Studies in Rats. Endocrinology. 2002;143(6):2420–2426. doi:10.1210/endo.143.6.8840
   PubMed Web of Science ®Google Scholar
• Gribble FM, Williams L, Simpson AK, Reimann F. A Novel Glucose-Sensing Mechanism Contributing to Glucagon-Like Peptide-1 Secretion From the GLUTag Cell Line. Diabetes. 2003;52(5):1147. doi:10.2337/diabetes.52.5.1147
   PubMed Web of Science ®Google Scholar
• Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: mechanisms of action. Drug Discovery Today. 2016;21(5):802–818. doi:10.1016/j.drudis.2016.01.013
   PubMed Web of Science ®Google Scholar
• Andreas Nygaard M, Gitte H, Sarah Juel P, et al. Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. J Endocrinol. 2010;206(3):287–296. doi:10.1677/JOE-10-0004
   PubMed Web of Science ®Google Scholar
• Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab. 2008;8(6):532–539. doi:10.1016/j.cmet.2008.11.002
   PubMed Web of Science ®Google Scholar
• Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obesity Metab. 2014;16(8):673–688. doi:10.1111/dom.12251
   PubMed Web of Science ®Google Scholar
• Robinson E, Tate M, Lockhart S, et al. Metabolically-inactive glucagon-like peptide-1(9–36)amide confers selective protective actions against post-myocardial infarction remodelling. Cardiovascular Diabetology. 2016;15(1):65. doi:10.1186/s12933-016-0386-5
   PubMedGoogle Scholar
• Sharma R, McDonald TS, Eng H, et al. In Vitro Metabolism of the Glucagon-Like Peptide-1 (GLP-1)–Derived Metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in Mouse and Human Hepatocytes. Drug Metab. Dispos. 2013;41(12):2148. doi:10.1124/dmd.113.054254
   PubMed Web of Science ®Google Scholar
• Habener JF, Stanojevic V. Pancreas and Not Gut Mediates the GLP-1-Induced Glucoincretin Effect. Cell Metab. 2017;25(4):757–758. doi:10.1016/j.cmet.2017.03.020
   PubMed Web of Science ®Google Scholar
• Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metabol. 2019;30:72–130. doi:10.1016/j.molmet.2019.09.010
   PubMed Web of Science ®Google Scholar
• Portha B, Tourrel-Cuzin C, Movassat J. Activation of the GLP-1 Receptor Signalling Pathway: a Relevant Strategy to Repair a Deficient Beta-Cell Mass. Exp Diabetes Res. 2011;2011:11. doi:10.1155/2011/376509
   Google Scholar
• Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Front Endocrinol. 2018;9(672):58. doi:10.3389/fendo.2018.00058
   PubMedGoogle Scholar
• Tamura K, Minami K, Kudo M, Iemoto K, Takahashi H, Seino S. Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice. PLoS One. 2015;10(5):e0126003. doi:10.1371/journal.pone.0126003
   PubMed Web of Science ®Google Scholar
• Garber AJ. Incretin effects on β-cell function, replication, and mass: the human perspective. Diabetes Care. 2011;34:S258–S263.
   PubMed Web of Science ®Google Scholar
• Xu G, Kaneto H, Lopez-Avalos MD, Weir GC, Bonner-Weir S. GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts. Diabetes Res Clin Pract. 2006;73(1):107–110. doi:10.1016/j.diabres.2005.11.007
   PubMed Web of Science ®Google Scholar
• Buteau J, Foisy S, Joly E, Prentki M. Glucagon-Like Peptide 1 Induces Pancreatic β-Cell Proliferation Via Transactivation of the Epidermal Growth Factor Receptor. Diabetes. 2003;52(1):124–132. doi:10.2337/diabetes.52.1.124
   PubMed Web of Science ®Google Scholar
• Biden TJ, Boslem E, Chu KY, Sue N. Lipotoxic endoplasmic reticulum stress, β cell failure, and type 2 diabetes mellitus. Trends Endocrinol Metab. 2014;25(8):389–398. doi:10.1016/j.tem.2014.02.003
   PubMed Web of Science ®Google Scholar
• Buteau J. GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival. Diabetes Metabolism. 2008;34:S73–S77.
   PubMed Web of Science ®Google Scholar
• Cunha DA, Ladrière L, Ortis F, et al. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes. 2009;58(12):2851–2862. doi:10.2337/db09-0685
   PubMed Web of Science ®Google Scholar
• Shin T, Naoki Y, Katsura T, et al. Protection of pancreatic β-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies. J Endocrinol. 2007;193(1):65–74. doi:10.1677/JOE-06-0148
   PubMed Web of Science ®Google Scholar
• Yusta B, Baggio LL, Estall JL, et al. GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 2006;4(5):391–406. doi:10.1016/j.cmet.2006.10.001
   PubMed Web of Science ®Google Scholar
• Arden C. A role for Glucagon-Like Peptide-1 in the regulation of β-cell autophagy. Peptides. 2018;100:85–93. doi:10.1016/j.peptides.2017.12.002
   PubMed Web of Science ®Google Scholar
• Zummo FP, Cullen KS, Honkanen-Scott M, Shaw JAM, Lovat PE, Arden C. Glucagon-Like Peptide 1 Protects Pancreatic β-Cells From Death by Increasing Autophagic Flux and Restoring Lysosomal Function. Diabetes. 2017;66(5):1272–1285. doi:10.2337/db16-1009
   PubMed Web of Science ®Google Scholar
• Lim GE, Brubaker PL. Glucagon-Like Peptide 1 Secretion by the L-Cell. Diabetes. 2006;55(Supplement 2):S70–S77. doi:10.2337/db06-S020
   PubMed Web of Science ®Google Scholar
• Carlessi R, Chen Y, Rowlands J, et al. GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation. Sci Rep. 2017;7(1):2661. doi:10.1038/s41598-017-02838-2
   PubMedGoogle Scholar
• Cornu M, Modi H, Kawamori D, Kulkarni RN, Joffraud M, Thorens B. Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression. J Biol Chem. 2010;285(14):10538–10545. doi:10.1074/jbc.M109.091116
   PubMed Web of Science ®Google Scholar
• Rowlands J, Cruzat V, Carlessi R, Newsholme P. Insulin and IGF-1 receptor autocrine loops are not required for Exendin-4 induced changes to pancreatic β-cell bioenergetic parameters and metabolism in BRIN-BD11 cells. Peptides. 2018;100:140–149. doi:10.1016/j.peptides.2017.11.015
   PubMed Web of Science ®Google Scholar
• Simon Hughes PN D. Alpha cell function in type 1 diabetes. Br J Diabetes. 2014;14(2):45–51. doi:10.15277/bjdvd.2014.014
   Google Scholar
• Meier JJ, Gethmann A, Götze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006;49(3):452–458. doi:10.1007/s00125-005-0126-y
   PubMed Web of Science ®Google Scholar
• Sancho V, Daniele G, Lucchesi D, et al. Metabolic regulation of GLP-1 and PC1/3 in pancreatic α-cell line. PLoS One. 2017;12(11):e0187836. doi:10.1371/journal.pone.0187836
   PubMed Web of Science ®Google Scholar
• Campbell SA, Johnson J, Light PE. Evidence for the existence and potential roles of intra-islet glucagon-like peptide-1. Islets. 2021;13(1–2):32–50. doi:10.1080/19382014.2021.1889941
   PubMed Web of Science ®Google Scholar
• Saikia M, Holter MM, Donahue LR, et al. GLP-1 receptor signaling increases PCSK1 and β cell features in human α cells. JCI Insight. 2021;6(3). doi:10.1172/jci.insight.141851
   PubMed Web of Science ®Google Scholar
• Ramracheya R, Chapman C, Chibalina M, et al. GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca(2+) channels. Physiological Reports. 2018;6(17):e13852. doi:10.14814/phy2.13852
   PubMedGoogle Scholar
• Zhang Y, Parajuli KR, Fava GE, et al. GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner. Diabetes. 2019;68(1):34–44. doi:10.2337/db18-0317
   PubMed Web of Science ®Google Scholar
• Wettergren A, Petersen H, Orskov C, Christiansen J, Sheikh SP, Holst JJ. Glucagon-Like Peptide-1 7-36 Amide and Peptide YY from the L-Cell of the Ileal Mucosa Are Potent Inhibitors of Vagally Induced Gastric Acid Secretion in Man. Scand J Gastroenterol. 1994;29(6):501–505. doi:10.3109/00365529409092462
   PubMed Web of Science ®Google Scholar
• Maljaars PW, Peters HP, Mela DJ, M AA. Ileal brake: a sensible food target for appetite control: a review. Physiol Behav. 2008;95:271–281. doi:10.1016/j.physbeh.2008.07.018
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Investig. 1998;101(3):515–520. doi:10.1172/JCI990
   PubMed Web of Science ®Google Scholar
• Tang-Christensen M, Larsen PJ, Göke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271:848–856.
   PubMed Web of Science ®Google Scholar
• Turton MD, O’Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379(6560):69–72. doi:10.1038/379069a0
   PubMed Web of Science ®Google Scholar
• Burcelin R, Da Costa A, Drucker D, T B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes. 2001;50(8):1720–1728. doi:10.2337/diabetes.50.8.1720
   PubMed Web of Science ®Google Scholar
• Alruwaili H, Dehestani B, le Roux CW. Clinical Impact of Liraglutide as a Treatment of Obesity. Clin Pharmacol. 2021;13:53–60. doi:10.2147/CPAA.S276085
   PubMed Web of Science ®Google Scholar
• Wang JY, Wang QW, Yang XY, et al. GLP-1 receptor agonists for the treatment of obesity: role as a promising approach. Front Endocrinol. 2023;14:1085799. doi:10.3389/fendo.2023.1085799
   PubMed Web of Science ®Google Scholar
• Li J, Zheng J, Wang S, Lau HK, Fathi A, Wang Q. Cardiovascular Benefits of Native GLP-1 and its Metabolites: an Indicator for GLP-1-Therapy Strategies. Front Physiol. 2017;8:15. doi:10.3389/fphys.2017.00015
   PubMed Web of Science ®Google Scholar
• Okerson T, Chilton RJ. The Cardiovascular Effects of GLP-1 Receptor Agonists. Cardiovasc. Ther. 2012;30(3):e146–e155. doi:10.1111/j.1755-5922.2010.00256.x
   PubMed Web of Science ®Google Scholar
• Reed J, Kanamarlapudi V, Bain S. Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. Cardiovascular Endocrinol Metab. 2018;7(1):18–23. doi:10.1097/XCE.0000000000000147
   PubMed Web of Science ®Google Scholar
• Hein GJ, Baker C, Hsieh J, Farr S, Adeli K. GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production: evidence for Predominance of GLP-2–Stimulated Postprandial Lipemia in Normal and Insulin-Resistant States. Diabetes. 2013;62(2):373–381. doi:10.2337/db12-0202
   PubMed Web of Science ®Google Scholar
• Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 2008;30(8):1448–1460. doi:10.1016/j.clinthera.2008.08.006
   PubMed Web of Science ®Google Scholar
• Shah Z, Kampfrath T, Deiuliis JA, et al. Chronic DPP-4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis. Circulation. 2011;124(21):2338–2349.
   PubMed Web of Science ®Google Scholar
• Wright EJ, Farrell KA, Malik N, et al. Encapsulated Glucagon-Like Peptide-1-Producing Mesenchymal Stem Cells Have a Beneficial Effect on Failing Pig Hearts. Stem Cells Translational Med. 2012;1(10):759–769. doi:10.5966/sctm.2012-0064
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369(14):1317–1326. doi:10.1056/NEJMoa1307684
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013;369(14):1327–1335. doi:10.1056/NEJMoa1305889
   PubMed Web of Science ®Google Scholar
• Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–785. doi:10.1016/S2213-8587(19)30249-9
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563
   PubMed Web of Science ®Google Scholar
• Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nyström T. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Pept. 2009;157(1–3):8–13. doi:10.1016/j.regpep.2009.07.003
   PubMed Web of Science ®Google Scholar
• Ban K, Noyan-Ashraf MH, Hoefer J, Bolz -S-S, Drucker DJ, Husain M. Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways. Circulation. 2008;117(18):2340–2350. doi:10.1161/CIRCULATIONAHA.107.739938
   PubMed Web of Science ®Google Scholar
• Ban K, Kim K-H, Cho C-K, et al. Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor. Endocrinology. 2010;151(4):1520–1531. doi:10.1210/en.2009-1197
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001
   PubMed Web of Science ®Google Scholar
• Hogan AE, Tobin AM, Ahern T, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011;54(11):2745–2754. doi:10.1007/s00125-011-2232-3
   PubMed Web of Science ®Google Scholar
• Faurschou A, Gyldenløve M, Rohde U, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients – a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015;29(3):555–559. doi:10.1111/jdv.12629
   PubMed Web of Science ®Google Scholar
• Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nature med. 2011;17(11):1481–1489. doi:10.1038/nm.2513
   PubMed Web of Science ®Google Scholar
• Lebherz C, Schlieper G, Möllmann J, et al. GLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease. Am J Med. 2017;130(7):833–841.e833. doi:10.1016/j.amjmed.2017.03.010
   PubMed Web of Science ®Google Scholar
• Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes. 2009;58(9):2148–2161. doi:10.2337/db09-0626
   PubMed Web of Science ®Google Scholar
• Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes. 2008;57(12):3281–3288. doi:10.2337/db08-0688
   PubMed Web of Science ®Google Scholar
• Yusta B, Baggio LL, Koehler J, et al. GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R. Diabetes. 2015;64(7):2537. doi:10.2337/db14-1577
   PubMed Web of Science ®Google Scholar
• Bendotti G, Montefusco L, Lunati ME, et al. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol Res. 2022;182:106320. doi:10.1016/j.phrs.2022.106320
   PubMed Web of Science ®Google Scholar
• Gutzwiller J-P, Tschopp S, Bock A, et al. Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men. J Clin Endocrinol Metab. 2004;89(6):3055–3061. doi:10.1210/jc.2003-031403
   PubMed Web of Science ®Google Scholar
• Crajoinas RO, Oricchio FT, Pessoa TD, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol. 2011;301(2):F355–F363. doi:10.1152/ajprenal.00729.2010
   PubMed Web of Science ®Google Scholar
• Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011;54(4):965–978. doi:10.1007/s00125-010-2028-x
   PubMed Web of Science ®Google Scholar
• Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(9):839–848. doi:10.1056/NEJMoa1616011
   PubMed Web of Science ®Google Scholar
• Kawanami D, Takashi Y. GLP-1 Receptor Agonists in Diabetic Kidney Disease: from Clinical Outcomes to Mechanisms. Front Pharmacol. 2020;11(967). doi:10.3389/fphar.2020.00967
   PubMedGoogle Scholar
• Giugliano D, Maiorino MI. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials. Int J Med. 2019;21(11):2576–2580. doi:10.1111/dom.13847
   Google Scholar
• Rossing P, Baeres FMM, Bakris G, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrology Dialysis Transplantation. 2023;38(9):2041–2051. doi:10.1093/ndt/gfad009
   PubMed Web of Science ®Google Scholar
• Williams DM, Evans M. Semaglutide: charting New Horizons in GLP-1 Analogue Outcome Studies. Diabetes Therapy. 2020;11(10):2221–2235. doi:10.1007/s13300-020-00917-8
   PubMed Web of Science ®Google Scholar
• Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. J Neurosci Res. 2003;72(5):603–612. doi:10.1002/jnr.10611
   PubMed Web of Science ®Google Scholar
• Gault VA, Hölscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur. J. Pharmacol. 2008;587(1):112–117. doi:10.1016/j.ejphar.2008.03.025
   PubMed Web of Science ®Google Scholar
• Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664–1675. doi:10.1016/S0140-6736(17)31585-4
   PubMed Web of Science ®Google Scholar
• Foltynie T, Aviles-Olmos I. Exenatide as a potential treatment for patients with Parkinson’s disease: first steps into the clinic. Alzheimer’s Dementia. 2014;10(1):S38–S46. doi:10.1016/j.jalz.2013.12.005
   PubMedGoogle Scholar
• Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA. 2009;106(4):1285–1290. doi:10.1073/pnas.0806720106
   PubMed Web of Science ®Google Scholar
• Li Y, Chigurupati S, Holloway H, et al. Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis. PLoS One. 2012;7:78.
   Web of Science ®Google Scholar
• Brierley DI, Holt MK, Singh A. Central and peripheral GLP-1 systems independently suppress eating. Feb. 2021;3(2):258–273.
   Google Scholar
• Nørgaard CH, Friedrich S, Hansen CT, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer's Dementia. 2022;8(1):e12268.
   Web of Science ®Google Scholar
• Raab EL, Vuguin PM, Stoffers DA, Simmons RA. Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats. Am J Physiol. 2009;297(6):R1785–R1794. doi:10.1152/ajpregu.00519.2009
   Google Scholar
• Redondo A, Trigo M, Acitores A, Valverde I, Villanueva-Peñacarrillo M. Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol. 2003;204:43–50. doi:10.1016/S0303-7207(03)00146-1
   PubMed Web of Science ®Google Scholar
• Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011;31(9):1285–1297. doi:10.1111/j.1478-3231.2011.02462.x
   PubMed Web of Science ®Google Scholar
• Hiroaki Y, Wataru A. Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis. BMJ Open Gastroenterology. 2020;7(1):e000370. doi:10.1136/bmjgast-2019-000370
   PubMed Web of Science ®Google Scholar
• Gonzalez N, Acitores A, Sancho V, Valverde I, VillanuevaPenacarrillo M. Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept. 2005;126:203–211. doi:10.1016/j.regpep.2004.10.002
   PubMedGoogle Scholar
• Luque M, Gonzalez N, Marquez L, et al. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol. 2002;173(3):465–473. doi:10.1677/joe.0.1730465
   PubMed Web of Science ®Google Scholar
• Yang H, Egan J, Wang Y, et al. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am J Physiol Cell Physiol. 1998;275(3):675–683. doi:10.1152/ajpcell.1998.275.3.C675
   Web of Science ®Google Scholar
• Wu L, Zhou M, Li T, et al. GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway. Biochimica et Biophysica Acta. 2022;1869(9):119300. doi:10.1016/j.bbamcr.2022.119300
   Web of Science ®Google Scholar
• Egan JM, Montrose Rafizadeh C, Wang Y, Bernier M, R J. Glucagon-like peptide-1 (7–36) amide (GLP-1) enhances insulin stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology. 1994;135:2070–2075. doi:10.1210/endo.135.5.7956929
   PubMed Web of Science ®Google Scholar
• Oben J, Morgan L, Fletcher J, Marks V. Effect of the enteropancreatic hormones, gastric inhibitory polypeptide and glucagon like polypeptide-1 (7–36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol. 1991;130:267–272. doi:10.1677/joe.0.1300267
   PubMed Web of Science ®Google Scholar
• Wang Y, Kole HK, Montrose-Rafizadeh C, Perfetti R, Bernier M, E JM. Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions. J Mol Endocrinol. 1997;19:241–248. doi:10.1677/jme.0.0190241
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhu C, Lu M, et al. The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution. J Endocrinol. 2019;240(2):271–286. doi:10.1530/JOE-18-0374
   PubMed Web of Science ®Google Scholar
• Ejarque M, Guerrero-Pérez F, De la morena N, et al. Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes. Apr. 2019;9(1):6274.
   Google Scholar
• Yamada C, Yamada Y, Tsukiyama K, et al. The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption. Endocrinology. 2008;149(2):574–579. doi:10.1210/en.2007-1292
   PubMed Web of Science ®Google Scholar
• Lamari Y, Boissard C, Moukhtar MS, Jullienne A, Rosselin G, Garel JM. Expression of glucagon-like peptide 1 receptor in a murine C cell line Regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett. 1996;393(2–3):248–252. doi:10.1016/0014-5793(96)00895-2
   PubMed Web of Science ®Google Scholar
• Nuche-Berenguer B, Moreno P, Portal-Nuñez S, Dapía S, Esbrit P, Villanueva-Peñacarrillo ML. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept. 2010;159(1–3):61–66. doi:10.1016/j.regpep.2009.06.010
   PubMedGoogle Scholar
• Xie B, Chen S, Xu Y, et al. The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment. Front Pharmacol. 2021;12.
   Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228–1239. doi:10.1056/NEJMoa1612917
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247–2257. doi:10.1056/NEJMoa1509225
   PubMed Web of Science ®Google Scholar
• Richter G, Feddersen O, Wagner U, Barth P, Goke R, G B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol Lung Cell Mol Physiol. 1993;265(4):374–381. doi:10.1152/ajplung.1993.265.4.L374
   Google Scholar
• Wang W, Mei A, Qian H, et al. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease. Pulmonary Dis. 2023;18:129–137.
   Google Scholar
• Altintas Dogan AD, Hilberg O, Hess S, Jensen TT, Bladbjerg EM. Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease. Int J Med. 2022;17:405–414. doi:10.2147/COPD.S350133
   Google Scholar
• Scrocchi LA, Brown TJ, MaClusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Med. 1996;2(11):1254–1258. doi:10.1038/nm1196-1254
   PubMed Web of Science ®Google Scholar
• Ahrén B, Yamada Y, Seino Y. The Insulin Response to Oral Glucose in GIP and GLP-1 Receptor Knockout Mice: review of the Literature and Stepwise Glucose Dose Response Studies in Female Mice. Front Endocrinol. 2021;12.
   Web of Science ®Google Scholar
• Ussher JR, Baggio LL, Campbell JE, et al. Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metabol. 2014;3(5):507–517. doi:10.1016/j.molmet.2014.04.009
   PubMed Web of Science ®Google Scholar
• Smith EP, An Z, Wagner C, et al. The role of β-cell GLP-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 2014;19(6):1050–1057. doi:10.1016/j.cmet.2014.04.005
   PubMed Web of Science ®Google Scholar
• Ayala JE, Bracy DP, James FD, Burmeister MA, Wasserman DH, Drucker DJ. Glucagon-Like Peptide-1 Receptor Knockout Mice Are Protected from High-Fat Diet-Induced Insulin Resistance. Endocrinology. 2010;151(10):4678–4687. doi:10.1210/en.2010-0289
   PubMed Web of Science ®Google Scholar
• McIntosh CHS, Widenmaier S, Kim SJ. Chapter 15 Glucose-Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitamin hormon. 2009;80:409–471.
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients. Diabetes. 2001;50(3):609–613. doi:10.2337/diabetes.50.3.609
   PubMed Web of Science ®Google Scholar
• Vollmer K, Holst JJ, Baller B, et al. Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance. Diabetes. 2008;57(3):678–687. doi:10.2337/db07-1124
   PubMed Web of Science ®Google Scholar
• Psichas A, Glass LL, Sharp SJ, Reimann F, Gribble FM. Galanin inhibits GLP‐1 and GIP secretion via the GAL(1) receptor in enteroendocrine L and K cells. Br. J. Pharmacol. 2016;173(5):888–898. doi:10.1111/bph.13407
   PubMed Web of Science ®Google Scholar
• Kieffer T, McIntosh C, Pederson R. Degradation of glucose‐dependent insulinotropic polypeptide and truncated glucagon‐like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136:3585–3596. doi:10.1210/endo.136.8.7628397
   PubMed Web of Science ®Google Scholar
• Preitner F, Ibberson M, Franklin I, et al. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Investig. 2004;113(4):635–645. doi:10.1172/JCI200420518
   PubMed Web of Science ®Google Scholar
• Taminato T, Seino Y, Goto Y, et al. Synthetic Gastric Inhibitory Polypeptide Stimulatory Effect on Insulin and Glucagon Secretion in the Rat. Diabetes. 1977;26(5):480–484. doi:10.2337/diab.26.5.480
   PubMed Web of Science ®Google Scholar
• Chia CW, Carlson OD, Kim W, et al. Exogenous Glucose–Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes. Diabetes. 2009;58(6):1342–1349. doi:10.2337/db08-0958
   PubMed Web of Science ®Google Scholar
• Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia. 2003;46(6):798–801. doi:10.1007/s00125-003-1103-y
   PubMed Web of Science ®Google Scholar
• Lynn FC, Pamir N, Ng EHC, McIntosh CHS, Kieffer TJ, Pederson RA. Defective Glucose-Dependent Insulinotropic Polypeptide Receptor Expression in Diabetic Fatty Zucker Rats. Diabetes. 2001;50(5):1004–1011. doi:10.2337/diabetes.50.5.1004
   PubMed Web of Science ®Google Scholar
• El K, Campbell JE. The role of GIP in α-cells and glucagon secretion. Peptides. 2020;125:170213. doi:10.1016/j.peptides.2019.170213
   PubMed Web of Science ®Google Scholar
• Mj BB. Gastric inhibitory polypeptide enhancement of the insulin effect on fatty acid incorporation into adipose tissue in the rat. Regul Pept. 1983;7:3–8. doi:10.1016/0167-0115(83)90276-8
   PubMedGoogle Scholar
• Thomsen C, Rasmussen O, Lousen T, et al. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr. 1999;69(6):1135–1143. doi:10.1093/ajcn/69.6.1135
   PubMed Web of Science ®Google Scholar
• Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Med. 2002;8(7):738–742. doi:10.1038/nm727
   PubMed Web of Science ®Google Scholar
• Naitoh R, Miyawaki K, Harada N, et al. Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice. Biochem. Biophys. Res. Commun. 2008;376(1):21–25. doi:10.1016/j.bbrc.2008.08.052
   PubMed Web of Science ®Google Scholar
• Zhou H, Yamada Y, Tsukiyama K, et al. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochem. Biophys. Res. Commun. 2005;335(3):937–942. doi:10.1016/j.bbrc.2005.07.164
   PubMed Web of Science ®Google Scholar
• Althage MC, Ford EL, Wang S, Tso P, Polonsky KS, Wice BM. Targeted Ablation of Glucose-dependent Insulinotropic Polypeptide-producing Cells in Transgenic Mice Reduces Obesity and Insulin Resistance Induced by a High Fat Diet. J Biol Chem. 2008;283(26):18365–18376. doi:10.1074/jbc.M710466200
   PubMed Web of Science ®Google Scholar
• Irwin N, McClean PL, O’Harte FPM, Gault VA, Harriott P, Flatt PR. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia. 2007;50(7):1532–1540. doi:10.1007/s00125-007-0692-2
   PubMed Web of Science ®Google Scholar
• Thondam SK, Cuthbertson DJ, Wilding JPH. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). Peptides. 2020;125:170208. doi:10.1016/j.peptides.2019.170208
   PubMed Web of Science ®Google Scholar
• Ceperuelo-Mallafré V, Duran X, Pachón G, et al. Disruption of GIP/GIPR Axis in Human Adipose Tissue Is Linked to Obesity and Insulin Resistance. J Clin Endocrinol Metab. 2014;99(5):E908–E919. doi:10.1210/jc.2013-3350
   PubMed Web of Science ®Google Scholar
• Starich GH, Bar RS, Mazzaferri EL. GIP increases insulin receptor affinity and cellular sensitivity in adipocytes. Am J Physiol. 1985;249(6 Pt 1):E603–607. doi:10.1152/ajpendo.1985.249.6.E603
   PubMedGoogle Scholar
• Bollag RJ, Zhong Q, Ding KH, et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol. 2001;177(1–2):35–41. doi:10.1016/S0303-7207(01)00405-1
   PubMed Web of Science ®Google Scholar
• Tsukiyama K, Yamada Y, Yamada C, et al. Gastric Inhibitory Polypeptide as an Endogenous Factor Promoting New Bone Formation after Food Ingestion. Mol Endocrinol. 2006;20(7):1644–1651. doi:10.1210/me.2005-0187
   PubMedGoogle Scholar
• Xie D, Zhong Q, Ding K-H, et al. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone. 2007;40(5):1352–1360. doi:10.1016/j.bone.2007.01.007
   PubMed Web of Science ®Google Scholar
• Stensen S, Gasbjerg LS, Helsted MM, Hartmann B, Christensen MB, Knop FK. GIP and the gut-bone axis – physiological, pathophysiological and potential therapeutic implications. Peptides. 2020;125:170197. doi:10.1016/j.peptides.2019.170197
   PubMed Web of Science ®Google Scholar
• Skov-Jeppesen K, Svane MS, Martinussen C, et al. GLP-2 and GIP exert separate effects on bone turnover: a randomized, placebo-controlled, crossover study in healthy young men. Bone. 2019;125:178–185. doi:10.1016/j.bone.2019.05.014
   PubMed Web of Science ®Google Scholar
• Christensen MB, Lund A, Calanna S, et al. Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. J Clin Endocrinol Metab. 2018;103(1):288–294. doi:10.1210/jc.2017-01949
   PubMed Web of Science ®Google Scholar
• Hansen MS, Søe K, Christensen LL, et al. GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells. Eur J Endocrinol. 2023;188(1):144–157. doi:10.1093/ejendo/lvac004
   Web of Science ®Google Scholar
• Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 2021;33(4):833–844.e835. doi:10.1016/j.cmet.2021.01.015
   PubMed Web of Science ®Google Scholar
• Adriaenssens AE, Biggs EK, Darwish T, et al. Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake. Cell Metab. 2019;30(5):987–996.e986. doi:10.1016/j.cmet.2019.07.013
   PubMed Web of Science ®Google Scholar
• Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1?. Trends Endocrinol Metab. 2020;31(6):410–421. doi:10.1016/j.tem.2020.02.006
   PubMed Web of Science ®Google Scholar
• Salehi M, Aulinger B, D’Alessio DA. Effect of Glycemia on Plasma Incretins and the Incretin Effect During Oral Glucose Tolerance Test. Diabetes. 2012;61(11):2728.
   PubMed Web of Science ®Google Scholar
• Hansotia T, Baggio LL, Delmeire D, et al. Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors. Diabetes. 2004;53(5):1326–1335. doi:10.2337/diabetes.53.5.1326
   PubMed Web of Science ®Google Scholar
• Hansotia T, Maida A, Flock G, et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Investig. 2007;117(1):143–152. doi:10.1172/JCI25483
   PubMed Web of Science ®Google Scholar
• Ayala JE, Bracy DP, Hansotia T, et al. Insulin Action in the Double Incretin Receptor Knockout Mouse. Diabetes. 2008;57(2):288. doi:10.2337/db07-0704
   PubMed Web of Science ®Google Scholar
• Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Med. 2015;21(1):27–36. doi:10.1038/nm.3761
   PubMed Web of Science ®Google Scholar
• Holst JJ, Rosenkilde MM. GIP as a Therapeutic Target in Diabetes and Obesity: insight From Incretin Co-agonists. J Clin Endocrinol Metab. 2020;105(8):e2710–e2716. doi:10.1210/clinem/dgaa327
   PubMed Web of Science ®Google Scholar
• Cui J, Shang A, Wang W, Chen W. Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals. Life Sci. 2020;260:118339. doi:10.1016/j.lfs.2020.118339
   PubMed Web of Science ®Google Scholar
• Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — a Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972
   PubMed Web of Science ®Google Scholar
• Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. doi:10.1016/S0140-6736(22)02033-5
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2017;12(12):2032. doi:10.2215/CJN.11491116
   PubMed Web of Science ®Google Scholar
• Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight. 2017;2(14):e93751. doi:10.1172/jci.insight.93751
   PubMed Web of Science ®Google Scholar
• Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World j Diabetes. 2015;6(13):1246–1258. doi:10.4239/wjd.v6.i13.1246
   PubMed Web of Science ®Google Scholar
• Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care. 2011;34(1):90–95. doi:10.2337/dc10-1393
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130. doi:10.1016/S0140-6736(19)31149-3
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841–851. doi:10.1056/NEJMoa1901118
   PubMed Web of Science ®Google Scholar